Overall impact
C (47)

Commentary

Moderna is an average overall performer. With a 'C' rating of 46.6 for overall impact (34th percentile compared to all companies), Moderna ranks 569th out of 585 industry peers, behind Grifols, Biogen, Ionis Pharmaceuticals and 565 others, and ahead of Jazz Pharmaceuticals, Outlook Therapeutics, Infinity Pharmaceuticals and 13 others. On top material causes for Moderna's industry (Pharmaceuticals & Biotech), Moderna performs well in Disease Eradication (96.7 score) and performs poorly in Sustainable Use of Water (1.6 score), Reduced Waste (32.9), Child and Maternal Health (27.5) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause MRNA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
5,800
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ma, United States
Share classes
MRNA
Mission
To deliver on the promise of mRNA science to make transformative medicines for patients.
Description
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine. Latent vaccines comprise cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines. Enteric viruses include norovirus. Public health vaccines consist of Zika, Nipah, and Mpox vaccines, while bacterial disease vaccines include Lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy, and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, Crigler-Najjar syndrome type 1, and cystic fibrosis. The company has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. Moderna, Inc. was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Material causes
Ethos considers the following causes material for Moderna, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.